Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Daniel Wirth, Ramesh Dass, Robert Hettle

ABSTRACT

BACKGROUND: Treatment of multidrug-resistant tuberculosis (MDR-TB) is complex, lengthy, and involves a minimum of four drugs termed a background regimen (BR), that have not previously been prescribed or that have proven susceptible to patient sputum culture isolates. In recent years, promising new treatment options have emerged as add-on therapies to a BR. The aim of this study was to evaluate the long-term costs and effectiveness of adding the novel or group 5 interventions bedaquiline, delamanid, and linezolid to a background regimen (BR) of drugs for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis (MDR-TB), within their marketing authorisations, from a German healthcare cost-effectiveness perspective. METHODS: A cohort-based Markov model was developed to simulate the incremental cost-effectiveness ratio of bedaquiline plus BR, delamanid plus BR, or linezolid plus BR versus BR alone in the treatment of MDR-TB, over a 10-year time horizon. Effectiveness of treatment was evaluated in Quality-Adjusted Life-Years (QALYs) and Life-Years Gained (LYG), using inputs from clinical trials for bedaquiline and delamanid and from a German observational study for linezolid. Cost data were obtained from German Drug Directory costs (€/2015), published literature, and expert opinion. A 3% yearly discount rate was applied. Probabilistic and deterministic sensitivity analyses were conducted. RESULTS: The total discounted costs per-patient were €85,575 for bedaquiline plus BR, €81,079 for delamanid plus BR, and €80,460 for linezolid plus BR, compared with a cost of €60,962 for BR alone. The total discounted QALYs per-patient were 5.95 for bedaquiline plus BR, 5.36 for delamanid plus BR, and 3.91 for linezolid plus BR, compared with 3.68 for BR alone. All interventions were therefore associated with higher QALYs and higher costs than BR alone, with incremental costs per QALY gained of €22,238 for bedaquiline, €38,703 for delamanid, and €87,484 for linezolid, versus BR alone. In a fully incremental analysis, bedaquiline plus BR was the most cost-effective treatment option at thresholds greater than €22,000 per QALY gained. In probabilistic analyses, the probability that bedaquiline plus BR was the most cost-effective treatment strategy at a willingness-to-pay threshold of €30,000 was 54.5%, compared with 22.9% for BR alone, 18.2% for delamanid plus BR, and 4.4% for linezolid. CONCLUSIONS: In Germany, the addition of bedaquiline, delamanid, or linezolid to a BR would result in QALY gains over BR alone. Based on this analysis, bedaquiline is likely to be the most cost-effective intervention for the treatment of MDR-TB, when added to a BR regimen at thresholds greater than €22,000 per QALY. More... »

PAGES

182

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12913-017-2118-2

DOI

http://dx.doi.org/10.1186/s12913-017-2118-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084250973

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28270207


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antitubercular Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diarylquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Germany", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Linezolid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitroimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Observational Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tuberculosis, Multidrug-Resistant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tuberculosis, Pulmonary", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Health Economics & Market Access, Janssen-Cilag GmbH, Johnson & Johnson Platz 1, 41470, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wirth", 
        "givenName": "Daniel", 
        "id": "sg:person.01310476327.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310476327.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Janssen-Cilag Ltd, High Wycombe, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dass", 
        "givenName": "Ramesh", 
        "id": "sg:person.010735026517.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010735026517.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PAREXEL International (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.477778.c", 
          "name": [
            "PAREXEL International, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hettle", 
        "givenName": "Robert", 
        "id": "sg:person.015540515717.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015540515717.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1183/09031936.00188313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000816364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1313865", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001016018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00035114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007696577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00035114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007696577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00035114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007696577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1745-6215-15-353", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008451801", 
          "https://doi.org/10.1186/1745-6215-15-353"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cid/ciu786", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011526331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5588/ijtld.11.0098", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012107494"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112433", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013478777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2014.08.2503", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016705676"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5588/ijtld.14.0944", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020353766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0017601", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020605446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2005/961613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021571984"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2005/961613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021571984"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1201964", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026353191"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/588292", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026417633"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00009509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026953280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0120763", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030774623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0120763", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030774623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00811-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036327320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00811-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036327320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00811-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036327320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1500286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037024841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1500286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037024841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1500286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037024841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x12458348", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040591509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x12458348", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040591509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.rmed.2014.09.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041854548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-662-43487-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042647015", 
          "https://doi.org/10.1007/978-3-662-43487-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-662-43487-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042647015", 
          "https://doi.org/10.1007/978-3-662-43487-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.rmed.2015.01.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046048646"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0120161", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047630997"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thx.2005.051961", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047713540"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thx.2005.051961", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047713540"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1415332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050159389"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00724-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050269155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00724-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050269155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00724-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050269155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-016-0443-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053258203", 
          "https://doi.org/10.1007/s40261-016-0443-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-016-0443-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053258203", 
          "https://doi.org/10.1007/s40261-016-0443-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0031-1291619", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057249590"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0034-1391920", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057326566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkv215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059735941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2807/1560-7917.es.2015.20.49.30087", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070925812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075021122", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078145716", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078630798", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3978/j.issn.2072-1439.2015.03.10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079087085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1989.7.1.36", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079159174"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Treatment of multidrug-resistant tuberculosis (MDR-TB) is complex, lengthy, and involves a minimum of four drugs termed a background regimen (BR), that have not previously been prescribed or that have proven susceptible to patient sputum culture isolates. In recent years, promising new treatment options have emerged as add-on therapies to a BR. The aim of this study was to evaluate the long-term costs and effectiveness of adding the novel or group 5 interventions bedaquiline, delamanid, and linezolid to a background regimen (BR) of drugs for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis (MDR-TB), within their marketing authorisations, from a German healthcare cost-effectiveness perspective.\nMETHODS: A cohort-based Markov model was developed to simulate the incremental cost-effectiveness ratio of bedaquiline plus BR, delamanid plus BR, or linezolid plus BR versus BR alone in the treatment of MDR-TB, over a 10-year time horizon. Effectiveness of treatment was evaluated in Quality-Adjusted Life-Years (QALYs) and Life-Years Gained (LYG), using inputs from clinical trials for bedaquiline and delamanid and from a German observational study for linezolid. Cost data were obtained from German Drug Directory costs (\u20ac/2015), published literature, and expert opinion. A 3% yearly discount rate was applied. Probabilistic and deterministic sensitivity analyses were conducted.\nRESULTS: The total discounted costs per-patient were \u20ac85,575 for bedaquiline plus BR, \u20ac81,079 for delamanid plus BR, and \u20ac80,460 for linezolid plus BR, compared with a cost of \u20ac60,962 for BR alone. The total discounted QALYs per-patient were 5.95 for bedaquiline plus BR, 5.36 for delamanid plus BR, and 3.91 for linezolid plus BR, compared with 3.68 for BR alone. All interventions were therefore associated with higher QALYs and higher costs than BR alone, with incremental costs per QALY gained of \u20ac22,238 for bedaquiline, \u20ac38,703 for delamanid, and \u20ac87,484 for linezolid, versus BR alone. In a fully incremental analysis, bedaquiline plus BR was the most cost-effective treatment option at thresholds greater than \u20ac22,000 per QALY gained. In probabilistic analyses, the probability that bedaquiline plus BR was the most cost-effective treatment strategy at a willingness-to-pay threshold of \u20ac30,000 was 54.5%, compared with 22.9% for BR alone, 18.2% for delamanid plus BR, and 4.4% for linezolid.\nCONCLUSIONS: In Germany, the addition of bedaquiline, delamanid, or linezolid to a BR would result in QALY gains over BR alone. Based on this analysis, bedaquiline is likely to be the most cost-effective intervention for the treatment of MDR-TB, when added to a BR regimen at thresholds greater than \u20ac22,000 per QALY.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12913-017-2118-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1327417", 
        "issn": [
          "1472-6963"
        ], 
        "name": "BMC Health Services Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany", 
    "pagination": "182", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d67df5fd4f4f80c08de2ec96dfa2344dcaebc08a957441cb3384d3d116f7c719"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28270207"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101088677"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12913-017-2118-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084250973"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12913-017-2118-2", 
      "https://app.dimensions.ai/details/publication/pub.1084250973"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54325_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12913-017-2118-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2118-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2118-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2118-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2118-2'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      21 PREDICATES      84 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12913-017-2118-2 schema:about N00b1260be266451eb8d35973d990db00
2 N0c00b4dd4da94e43a134064c0bebaefc
3 N14e37dd852b34658b885ce08922a79ab
4 N16e41722bc564db3bce33b1063fe6bad
5 N212e17a1f24a42be9ae90d7ff1bc03c7
6 N47331a14125d4d2083a94434eb97655e
7 N4a7d1d006ca44652b804ace0d700fcea
8 N4ece738ef65444eb8811f6df7189d998
9 N771a7f923b964025976d92fc0d1d800f
10 N80cca8f498b54d8a8a0500ac9766838c
11 N8a371d7c78c24ca0acdc6275c00a4744
12 Nb27bb5f78b0d48b9bbd2e9b1e37376dd
13 Nc717c143278f402ebc4e6fb2614a82b6
14 Nc9d10e99876c44b981f091a82637f4d9
15 Ncf896914048445a6979dec8ab7c79624
16 Nd77d740a168541ccbae00d70235be51a
17 Nd93536693fa44ef59e23ef455728b609
18 Ndff23236f66b4613857e532e227d3086
19 Ne413a587d9074ca893183232bd9e3bcf
20 Ne469ec125dd345188e6fe355e258e011
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N79d75ba090234041abd2e27176c0dcdc
24 schema:citation sg:pub.10.1007/978-3-662-43487-1
25 sg:pub.10.1007/s40261-016-0443-6
26 sg:pub.10.1186/1745-6215-15-353
27 https://app.dimensions.ai/details/publication/pub.1075021122
28 https://app.dimensions.ai/details/publication/pub.1078145716
29 https://app.dimensions.ai/details/publication/pub.1078630798
30 https://doi.org/10.1016/j.jval.2014.08.2503
31 https://doi.org/10.1016/j.rmed.2014.09.021
32 https://doi.org/10.1016/j.rmed.2015.01.017
33 https://doi.org/10.1055/s-0031-1291619
34 https://doi.org/10.1055/s-0034-1391920
35 https://doi.org/10.1056/nejmc1415332
36 https://doi.org/10.1056/nejmc1500286
37 https://doi.org/10.1056/nejmoa1112433
38 https://doi.org/10.1056/nejmoa1201964
39 https://doi.org/10.1056/nejmoa1313865
40 https://doi.org/10.1086/588292
41 https://doi.org/10.1093/cid/ciu786
42 https://doi.org/10.1093/jac/dkv215
43 https://doi.org/10.1136/thx.2005.051961
44 https://doi.org/10.1155/2005/961613
45 https://doi.org/10.1177/0272989x12458348
46 https://doi.org/10.1183/09031936.00009509
47 https://doi.org/10.1183/09031936.00035114
48 https://doi.org/10.1183/09031936.00188313
49 https://doi.org/10.1183/13993003.00724-2015
50 https://doi.org/10.1183/13993003.00811-2015
51 https://doi.org/10.1200/jco.1989.7.1.36
52 https://doi.org/10.1371/journal.pone.0017601
53 https://doi.org/10.1371/journal.pone.0120161
54 https://doi.org/10.1371/journal.pone.0120763
55 https://doi.org/10.2807/1560-7917.es.2015.20.49.30087
56 https://doi.org/10.3978/j.issn.2072-1439.2015.03.10
57 https://doi.org/10.5588/ijtld.11.0098
58 https://doi.org/10.5588/ijtld.14.0944
59 schema:datePublished 2017-12
60 schema:datePublishedReg 2017-12-01
61 schema:description BACKGROUND: Treatment of multidrug-resistant tuberculosis (MDR-TB) is complex, lengthy, and involves a minimum of four drugs termed a background regimen (BR), that have not previously been prescribed or that have proven susceptible to patient sputum culture isolates. In recent years, promising new treatment options have emerged as add-on therapies to a BR. The aim of this study was to evaluate the long-term costs and effectiveness of adding the novel or group 5 interventions bedaquiline, delamanid, and linezolid to a background regimen (BR) of drugs for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis (MDR-TB), within their marketing authorisations, from a German healthcare cost-effectiveness perspective. METHODS: A cohort-based Markov model was developed to simulate the incremental cost-effectiveness ratio of bedaquiline plus BR, delamanid plus BR, or linezolid plus BR versus BR alone in the treatment of MDR-TB, over a 10-year time horizon. Effectiveness of treatment was evaluated in Quality-Adjusted Life-Years (QALYs) and Life-Years Gained (LYG), using inputs from clinical trials for bedaquiline and delamanid and from a German observational study for linezolid. Cost data were obtained from German Drug Directory costs (€/2015), published literature, and expert opinion. A 3% yearly discount rate was applied. Probabilistic and deterministic sensitivity analyses were conducted. RESULTS: The total discounted costs per-patient were €85,575 for bedaquiline plus BR, €81,079 for delamanid plus BR, and €80,460 for linezolid plus BR, compared with a cost of €60,962 for BR alone. The total discounted QALYs per-patient were 5.95 for bedaquiline plus BR, 5.36 for delamanid plus BR, and 3.91 for linezolid plus BR, compared with 3.68 for BR alone. All interventions were therefore associated with higher QALYs and higher costs than BR alone, with incremental costs per QALY gained of €22,238 for bedaquiline, €38,703 for delamanid, and €87,484 for linezolid, versus BR alone. In a fully incremental analysis, bedaquiline plus BR was the most cost-effective treatment option at thresholds greater than €22,000 per QALY gained. In probabilistic analyses, the probability that bedaquiline plus BR was the most cost-effective treatment strategy at a willingness-to-pay threshold of €30,000 was 54.5%, compared with 22.9% for BR alone, 18.2% for delamanid plus BR, and 4.4% for linezolid. CONCLUSIONS: In Germany, the addition of bedaquiline, delamanid, or linezolid to a BR would result in QALY gains over BR alone. Based on this analysis, bedaquiline is likely to be the most cost-effective intervention for the treatment of MDR-TB, when added to a BR regimen at thresholds greater than €22,000 per QALY.
62 schema:genre research_article
63 schema:inLanguage en
64 schema:isAccessibleForFree true
65 schema:isPartOf N1054b36cbee7465fbe2546aa34af914a
66 Ndc1b1f133bf54f21a1df065e13b121f9
67 sg:journal.1327417
68 schema:name Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
69 schema:pagination 182
70 schema:productId N29f904569bc04993b9026830cb7282ce
71 N2a39e5d838194192a8b34706e3db9787
72 N6eb02800c9184eac8d5a3feddf77566d
73 N83b4a0f1fe07425cbf7e2a8362ff71b5
74 N9aa007cbbdfa4acc82d32525923cf727
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084250973
76 https://doi.org/10.1186/s12913-017-2118-2
77 schema:sdDatePublished 2019-04-11T10:19
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher N5f606e4e56b841f99d4f0f0b95f31a17
80 schema:url https://link.springer.com/10.1186%2Fs12913-017-2118-2
81 sgo:license sg:explorer/license/
82 sgo:sdDataset articles
83 rdf:type schema:ScholarlyArticle
84 N00b1260be266451eb8d35973d990db00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Antitubercular Agents
86 rdf:type schema:DefinedTerm
87 N0c00b4dd4da94e43a134064c0bebaefc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Germany
89 rdf:type schema:DefinedTerm
90 N1054b36cbee7465fbe2546aa34af914a schema:issueNumber 1
91 rdf:type schema:PublicationIssue
92 N14e37dd852b34658b885ce08922a79ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Female
94 rdf:type schema:DefinedTerm
95 N16e41722bc564db3bce33b1063fe6bad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Drug Therapy, Combination
97 rdf:type schema:DefinedTerm
98 N212e17a1f24a42be9ae90d7ff1bc03c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Clinical Protocols
100 rdf:type schema:DefinedTerm
101 N29f904569bc04993b9026830cb7282ce schema:name dimensions_id
102 schema:value pub.1084250973
103 rdf:type schema:PropertyValue
104 N2a39e5d838194192a8b34706e3db9787 schema:name readcube_id
105 schema:value d67df5fd4f4f80c08de2ec96dfa2344dcaebc08a957441cb3384d3d116f7c719
106 rdf:type schema:PropertyValue
107 N37fffc9ee0d9427d9b3c97579b0f7c31 rdf:first sg:person.015540515717.99
108 rdf:rest rdf:nil
109 N47331a14125d4d2083a94434eb97655e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Treatment Outcome
111 rdf:type schema:DefinedTerm
112 N4a7d1d006ca44652b804ace0d700fcea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Observational Studies as Topic
114 rdf:type schema:DefinedTerm
115 N4ece738ef65444eb8811f6df7189d998 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Cost-Benefit Analysis
117 rdf:type schema:DefinedTerm
118 N5f606e4e56b841f99d4f0f0b95f31a17 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N6eb02800c9184eac8d5a3feddf77566d schema:name doi
121 schema:value 10.1186/s12913-017-2118-2
122 rdf:type schema:PropertyValue
123 N7608ef6eb7914bb79d10df5d44563ec4 schema:name Janssen-Cilag Ltd, High Wycombe, UK
124 rdf:type schema:Organization
125 N771a7f923b964025976d92fc0d1d800f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Male
127 rdf:type schema:DefinedTerm
128 N79d75ba090234041abd2e27176c0dcdc rdf:first sg:person.01310476327.89
129 rdf:rest Nfacc809afa364754aa4f4cff2f21e39f
130 N80cca8f498b54d8a8a0500ac9766838c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Adult
132 rdf:type schema:DefinedTerm
133 N83b4a0f1fe07425cbf7e2a8362ff71b5 schema:name pubmed_id
134 schema:value 28270207
135 rdf:type schema:PropertyValue
136 N8a371d7c78c24ca0acdc6275c00a4744 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Tuberculosis, Pulmonary
138 rdf:type schema:DefinedTerm
139 N9aa007cbbdfa4acc82d32525923cf727 schema:name nlm_unique_id
140 schema:value 101088677
141 rdf:type schema:PropertyValue
142 Nb27bb5f78b0d48b9bbd2e9b1e37376dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Diarylquinolines
144 rdf:type schema:DefinedTerm
145 Nc717c143278f402ebc4e6fb2614a82b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Drug Costs
147 rdf:type schema:DefinedTerm
148 Nc9d10e99876c44b981f091a82637f4d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Oxazoles
150 rdf:type schema:DefinedTerm
151 Ncf896914048445a6979dec8ab7c79624 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Quality-Adjusted Life Years
153 rdf:type schema:DefinedTerm
154 Nd77d740a168541ccbae00d70235be51a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Humans
156 rdf:type schema:DefinedTerm
157 Nd93536693fa44ef59e23ef455728b609 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Linezolid
159 rdf:type schema:DefinedTerm
160 Ndc1b1f133bf54f21a1df065e13b121f9 schema:volumeNumber 17
161 rdf:type schema:PublicationVolume
162 Ndff23236f66b4613857e532e227d3086 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Nitroimidazoles
164 rdf:type schema:DefinedTerm
165 Ne413a587d9074ca893183232bd9e3bcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Tuberculosis, Multidrug-Resistant
167 rdf:type schema:DefinedTerm
168 Ne469ec125dd345188e6fe355e258e011 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Clinical Trials as Topic
170 rdf:type schema:DefinedTerm
171 Nfacc809afa364754aa4f4cff2f21e39f rdf:first sg:person.010735026517.46
172 rdf:rest N37fffc9ee0d9427d9b3c97579b0f7c31
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
177 schema:name Clinical Sciences
178 rdf:type schema:DefinedTerm
179 sg:journal.1327417 schema:issn 1472-6963
180 schema:name BMC Health Services Research
181 rdf:type schema:Periodical
182 sg:person.010735026517.46 schema:affiliation N7608ef6eb7914bb79d10df5d44563ec4
183 schema:familyName Dass
184 schema:givenName Ramesh
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010735026517.46
186 rdf:type schema:Person
187 sg:person.01310476327.89 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
188 schema:familyName Wirth
189 schema:givenName Daniel
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310476327.89
191 rdf:type schema:Person
192 sg:person.015540515717.99 schema:affiliation https://www.grid.ac/institutes/grid.477778.c
193 schema:familyName Hettle
194 schema:givenName Robert
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015540515717.99
196 rdf:type schema:Person
197 sg:pub.10.1007/978-3-662-43487-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042647015
198 https://doi.org/10.1007/978-3-662-43487-1
199 rdf:type schema:CreativeWork
200 sg:pub.10.1007/s40261-016-0443-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053258203
201 https://doi.org/10.1007/s40261-016-0443-6
202 rdf:type schema:CreativeWork
203 sg:pub.10.1186/1745-6215-15-353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008451801
204 https://doi.org/10.1186/1745-6215-15-353
205 rdf:type schema:CreativeWork
206 https://app.dimensions.ai/details/publication/pub.1075021122 schema:CreativeWork
207 https://app.dimensions.ai/details/publication/pub.1078145716 schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1078630798 schema:CreativeWork
209 https://doi.org/10.1016/j.jval.2014.08.2503 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016705676
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.rmed.2014.09.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041854548
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/j.rmed.2015.01.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046048646
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1055/s-0031-1291619 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057249590
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1055/s-0034-1391920 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057326566
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1056/nejmc1415332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050159389
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1056/nejmc1500286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037024841
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1056/nejmoa1112433 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013478777
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1056/nejmoa1201964 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026353191
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1056/nejmoa1313865 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001016018
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1086/588292 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026417633
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/cid/ciu786 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011526331
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1093/jac/dkv215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059735941
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1136/thx.2005.051961 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047713540
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1155/2005/961613 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021571984
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1177/0272989x12458348 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040591509
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1183/09031936.00009509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026953280
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1183/09031936.00035114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007696577
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1183/09031936.00188313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000816364
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1183/13993003.00724-2015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050269155
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1183/13993003.00811-2015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036327320
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1200/jco.1989.7.1.36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079159174
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1371/journal.pone.0017601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020605446
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1371/journal.pone.0120161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047630997
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1371/journal.pone.0120763 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030774623
258 rdf:type schema:CreativeWork
259 https://doi.org/10.2807/1560-7917.es.2015.20.49.30087 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070925812
260 rdf:type schema:CreativeWork
261 https://doi.org/10.3978/j.issn.2072-1439.2015.03.10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079087085
262 rdf:type schema:CreativeWork
263 https://doi.org/10.5588/ijtld.11.0098 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012107494
264 rdf:type schema:CreativeWork
265 https://doi.org/10.5588/ijtld.14.0944 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020353766
266 rdf:type schema:CreativeWork
267 https://www.grid.ac/institutes/grid.477778.c schema:alternateName PAREXEL International (United Kingdom)
268 schema:name PAREXEL International, London, UK
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.497524.9 schema:alternateName Janssen (Germany)
271 schema:name Health Economics & Market Access, Janssen-Cilag GmbH, Johnson & Johnson Platz 1, 41470, Neuss, Germany
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...